Murphy & Mullick Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Murphy & Mullick Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42K	Sell	221 -44	-17%	-$7.56K	0.03%	324
2026 Q1	$44.7K	Buy	265 +6	+2%	+$1.03K	0.03%	297
2025 Q4	$43.7K	Buy	259 +7	+3%	+$1.14K	0.03%	304
2025 Q3	$38.3K	Buy	252 +6	+2%	+$819	0.03%	311
2025 Q2	$31.7K	Buy	246 +12	+5%	+$1.47K	0.03%	324
2025 Q1	$29.9K	Sell	234 -31	-12%	-$4.2K	0.03%	319
2024 Q4	$35K	Buy	+265	New	+$37.3K	0.03%	300

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Murphy & Mullick Capital Management's IBB Position: Q2 2026 in Review

Murphy & Mullick Capital Management reduced its iShares Biotechnology ETF (IBB) stake by 17% in Q2 2026, selling an estimated $7.56K and leaving 221 shares worth $42K. The position accounts for 0.03% of the portfolio, ranked #324.

Murphy & Mullick Capital Management first reported a position in IBB in Q4 2024 and has held it in 7 quarters since. The position peaked at $44.7K in Q1 2026. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Murphy & Mullick Capital Management held 221 shares of iShares Biotechnology ETF worth $42K as of Q2 2026.
Murphy & Mullick Capital Management sold 44 iShares Biotechnology ETF shares in Q2 2026, an estimated $7.56K.
iShares Biotechnology ETF made up 0.03% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #324 holding.
Murphy & Mullick Capital Management first reported a position in iShares Biotechnology ETF in Q4 2024 and has held it in 7 quarters since.
Murphy & Mullick Capital Management's iShares Biotechnology ETF position peaked at $44.7K in Q1 2026.
956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.